New Technology Centre with China’s Regenerative Medicine Industry
Pictured from left to right are: Professor Ian Walmsley, Mr Dai Yumin and Professor Zhanfeng Cui.To mark the official long-term collaboration agreement to establish the 'CBMRT Technology Centre at the University of Oxford,' a signing ceremony was recently held at the University’s Department of Engineering Science. Professor Ian Walmsley, Oxford University Pro-Vice-Chancellor (Research), and Mr Dai Yumin, Executive Director of CBMRT, signed the contract on behalf of each party. Mr Chen Futao, The Minister Chancellor of Science and Technology from the Chinese Embassy in London, also attended this special signing ceremony.
Guan Guoliang, Chairman of the Strategy Committee of CBMRT said: “We are delighted to have the opportunity to work with Oxford University. This signing ceremony marks the collaboration between western technology and Chinese industry. We aim to work together on regenerative medical technology that will have a significant impact on the quality of life of human beings. We believe that this long-term collaboration with the University of Oxford is an important milestone of the Company’s business strategy to expand internationally”.
Professor Ian Walmsley commented: “We are pleased to see our high quality research being recognised by industry worldwide. This is an important relationship for Oxford’s Engineering Science Department and the University”.
Exchanging of gifts at the signing ceremony.
Professor Zhanfeng Cui in his lab.The founding of this new Centre will lead to enterprise-specific research projects under the leadership of Professor Zhanfeng Cui, the renowned scientist and a Fellow of the Royal Academy of Engineering. After Rolls-Royce and Invensys Ltd., CBMRT is the third enterprise to set up such a research and development technology centre that is sponsored by enterprise and undertaking specific research at Oxford. The collaboration draws on expertise at Oxford University, including at its technology transfer company Isis Innovation, and elsewhere in translating research into commercial opportunities in China and creates a stronger bond with CBMRT. Oxford University and CBMRT are expected to enjoy a share of the medical market for years to come.
About China Bio-Med Regeneration Technology Limited
CBMRT is a Hong Kong listed company principally engaged in research and development of bio-medical and healthcare products, and medical techniques; the provision of the production and sales of tissue engineering products and its related by-products; as well as sales and distribution of medical products and equipment. CBMRT launched the first China Food and Drug Administration approved tissue-engineered skin, “ActivSkin”, in China’s market.
Department at the forefront of research
Professor Lionel Tarassenko speaking at the signing ceremony.Oxford’s Department of Engineering Science is at the forefront of research in the development of enabling technologies for tissue engineering and stem cell therapy. Professor Cui also has research interests in the technologies that will monitor and regulate tissue growth, and in cryo-preservation techniques. A further related area of research is into membrane processes.
Professor Lionel Tarassenko, Head of the Department of Engineering Science, said: “We welcome this support from CBMRT, which will provide funding to target major unmet clinical needs, including but not limited to diabetes, cancer, neural degradation and organ repairs using stem cells therapy”.
The signing ceremony was followed by a special tour of the Bodleian Library, where guests viewed rare Chinese books, and dinner at Hertford College.